PMID- 31713444
OWN - NLM
STAT- MEDLINE
DCOM- 20200323
LR  - 20200323
IS  - 2169-141X (Electronic)
IS  - 2169-1401 (Linking)
VI  - 47
IP  - 1
DP  - 2019 Dec
TI  - Co-encapsulation of magnetic Fe(3)O(4) nanoparticles and doxorubicin into 
      biocompatible PLGA-PEG nanocarriers for early detection and treatment of tumours.
PG  - 4211-4221
LID - 10.1080/21691401.2019.1687500 [doi]
AB  - At present, cancer is the first cause of death for humans, but early detection 
      and treatment can help improve prognoses and reduce mortality. However, further 
      development of carrier-assistant drug delivery systems (DDSs) is retarded by the 
      aspects such as the low drug-carrying capacity, carrier-induced toxicity and 
      immunogenicity, complex synthesis manipulation. The development of nanoscale drug 
      delivery systems (NDDS) have been rapidly developed to address these issues. In 
      this article, we used PLGA-PEG with good biocompatibility to encapsulate 
      Fe(3)O(4) nanoparticles (a magnetic resonance imaging contrast agent) and DOX (an 
      antitumour drug) via the emulsion-solvent evaporation method, aimed at achieving 
      a dual function of the early detection and the treatment of mammary cancer. The 
      results showed that the Fe(3)O(4)/DOX/PLGA-PEG nanoparticles had a relatively 
      uniform size, a high carrier rate of Fe(3)O(4) and high encapsulation efficiency 
      of DOX, and a relatively high activity of released DOX within 120 h. In addition, 
      in vitro studies showed that the Fe(3)O(4)/DOX/PLGA-PEG nanoparticles were 
      cytocompatibility in NIH 3T3 fibroblast cells culture study while had a special 
      effect on destroying human breast cancer MCF-7 cells compared with pure DOX 
      solution. In vitro studies revealed that the Fe(3)O(4)/DOX/PLGA-PEG enabled 
      enhanced T2 contrast magnetic resonance. Overall, our multifunctional 
      Fe(3)O(4)/DOX/PLGA-PEG nanoparticles, composed of biocompatible substances and 
      therapeutic/imaging materials, have great potential for the early detection of 
      cancer and accurate drug delivery via the dynamic monitoring using MRI.
FAU - Liang, Chenghua
AU  - Liang C
AD  - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, China.
FAU - Li, Nan
AU  - Li N
AD  - Department of Stomatology Center, Shenzhen People's Hospital, Second Clinical 
      Medical School of Jinan University, 1st Affiliated Hospital of Southern 
      University of Science and Technology, Shenzhen, China.
FAU - Cai, Zikai
AU  - Cai Z
AD  - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, China.
FAU - Liang, Rongpu
AU  - Liang R
AD  - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, China.
FAU - Zheng, Xiaoming
AU  - Zheng X
AD  - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, China.
FAU - Deng, Li
AU  - Deng L
AD  - Beogene Biotech (Guangzhou) CO., LTD, Guangzhou, China.
FAU - Feng, Longbao
AU  - Feng L
AD  - Beogene Biotech (Guangzhou) CO., LTD, Guangzhou, China.
FAU - Guo, Rui
AU  - Guo R
AD  - Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, 
      Guangdong Provincial Engineering and Technological Research Center for Drug 
      Carrier Development, Department of Biomedical Engineering, Jinan University, 
      Guangzhou, China.
FAU - Wei, Bo
AU  - Wei B
AD  - Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Artif Cells Nanomed Biotechnol
JT  - Artificial cells, nanomedicine, and biotechnology
JID - 101594777
RN  - 0 (Biocompatible Materials)
RN  - 0 (Capsules)
RN  - 0 (Drug Carriers)
RN  - 0 (Magnetite Nanoparticles)
RN  - 0 (Polyesters)
RN  - 0 (Solvents)
RN  - 0 (polyethylene glycol-poly(lactide-co-glycolide))
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - 3T3 Cells
MH  - Animals
MH  - Biocompatible Materials/*chemistry/metabolism
MH  - Biological Transport
MH  - Capsules
MH  - Doxorubicin/*chemistry/*therapeutic use
MH  - Drug Carriers/*chemistry/metabolism
MH  - Drug Liberation
MH  - *Early Detection of Cancer
MH  - Magnetic Resonance Imaging
MH  - Magnetite Nanoparticles/*chemistry
MH  - Mice
MH  - Particle Size
MH  - Polyesters/*chemistry
MH  - Polyethylene Glycols/*chemistry
MH  - Solvents/chemistry
OTO - NOTNLM
OT  - Fe3O4
OT  - MRI
OT  - PLGA-PEG nanoparticles
OT  - theranostics
OT  - tumour
EDAT- 2019/11/13 06:00
MHDA- 2020/03/24 06:00
CRDT- 2019/11/13 06:00
PHST- 2019/11/13 06:00 [entrez]
PHST- 2019/11/13 06:00 [pubmed]
PHST- 2020/03/24 06:00 [medline]
AID - 10.1080/21691401.2019.1687500 [doi]
PST - ppublish
SO  - Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4211-4221. doi: 
      10.1080/21691401.2019.1687500.